In yesterday’s Wall Street session, TCR2 Therapeutics Inc. (NASDAQ:TCRR) shares traded at $1.41, up 2.17% from the previous session.
As of this writing, 8 analysts cover TCR2 Therapeutics Inc. (NASDAQ:TCRR). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $2.00, we find $11.00. Given the previous closing price of $1.38, this indicates a potential upside of 697.1 percent. TCRR stock price is now -20.94% away from the 50-day moving average and -44.58% away from the 200-day moving average. The market capitalization of the company currently stands at $52.59M.
There are 3 analysts who have given it a hold rating, whereas 5 have given it a buy rating. Brokers who have rated the stock have averaged $11.00 as their price target over the next twelve months.
With the price target reduced from $28 to $5, Goldman Downgraded its rating from Buy to Neutral for TCR2 Therapeutics Inc. (NASDAQ: TCRR). , while ‘SVB Leerink’ rates the stock as ‘Mkt Perform’.
Insiders disposed of 265,459 shares of company stock worth roughly $0.37 million over the past 1 year. A total of 0.89% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TCRR stock. A new stake in TCR2 Therapeutics Inc. shares was purchased by JACOBS LEVY EQUITY MANAGEMENT, INC during the first quarter worth $118,000. UBS OCONNOR LLC invested $76,000 in shares of TCRR during the first quarter. In the first quarter, PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO acquired a new stake in TCR2 Therapeutics Inc. valued at approximately $27,000. BELVEDERE TRADING LLC acquired a new stake in TCRR for approximately $23,000. CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. purchased a new stake in TCRR valued at around $20,000 in the second quarter.
During the past 12 months, TCR2 Therapeutics Inc. has had a low of $1.27 and a high of $6.95. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.00, and a quick ratio of 5.00.
The company reported revenue of $31.1 million for the quarter, compared to $26.24 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 18.53 percent.